Alps Advisors Inc. Has $1,411,000 Stake in Achillion Pharmaceuticals Inc. (ACHN)
Alps Advisors Inc. decreased its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 9.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 174,246 shares of the biopharmaceutical company’s stock after selling 17,707 shares during the period. Alps Advisors Inc. owned about 0.13% of Achillion Pharmaceuticals worth $1,411,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in ACHN. Fox Run Management L.L.C. bought a new position in shares of Achillion Pharmaceuticals during the second quarter worth approximately $105,000. Investment Centers of America Inc. increased its position in shares of Achillion Pharmaceuticals by 27.7% in the second quarter. Investment Centers of America Inc. now owns 13,733 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 2,975 shares in the last quarter. Princeton Alpha Management LP bought a new position in shares of Achillion Pharmaceuticals during the second quarter worth approximately $109,000. Teacher Retirement System of Texas increased its position in shares of Achillion Pharmaceuticals by 13.0% in the second quarter. Teacher Retirement System of Texas now owns 15,173 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 1,749 shares in the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Achillion Pharmaceuticals by 523.6% in the third quarter. Quantbot Technologies LP now owns 15,310 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 12,855 shares in the last quarter. 78.45% of the stock is owned by institutional investors and hedge funds.
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded down 6.32% during midday trading on Monday, hitting $4.15. Achillion Pharmaceuticals Inc. has a 52 week low of $3.78 and a 52 week high of $10.95. The stock’s market capitalization is $567.22 million. The firm’s 50-day moving average price is $5.71 and its 200-day moving average price is $7.84.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. On average, equities research analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.61) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/29/alps-advisors-inc-has-1411000-stake-in-achillion-pharmaceuticals-inc-achn.html.
A number of brokerages have recently commented on ACHN. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Tuesday, August 9th. Wedbush assumed coverage on Achillion Pharmaceuticals in a report on Thursday, September 22nd. They issued an “outperform” rating and a $13.00 price target for the company. Robert W. Baird reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Achillion Pharmaceuticals in a report on Sunday, November 6th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of Achillion Pharmaceuticals in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $10.56.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.